Szkaradkiewicz-Karpińska Anna K, Szkaradkiewicz Andrzej
Department of Preclinical Conservative Dentistry and Preclinical Endodontics, University of Medical Sciences, 60-812 Poznań, Poland.
Institute of Health and Physical Culture, State Higher Vocational School, 64-100 Leszno, Poland.
Exp Ther Med. 2021 Jan;21(1):33. doi: 10.3892/etm.2020.9465. Epub 2020 Nov 11.
At the end of 2019, a new disease, similar to severe acute respiratory syndrome (SARS) associated with SARS-CoV was reported in Wuhan, China. It was quickly discovered that the etiological factor of the new disease (COVID-19) was a previously unknown SARS coronavirus 2 (SARS-CoV-2). The global spread of of COVID-19 has lead to the declaration of a pandemic status in 2019-2020 as declared by the World Health Organization and Public Health Emergency of International Concern. SARS-CoV-2 characterizes with high epidemic potential and is effectively disseminated between humans. SARS-CoV and SARS-CoV-2 are closely related pathogens. Their prime route of distribution is air-droplet transmission. Combating infectious diseases disseminated by inhalation is very difficult, and mainly relies on the use of vaccines. However, despite the lack of an effective anti-SARS-CoV vaccine and specific antiviral drugs, the strict sanitary procedures proved to be sufficient to stop the SARS epidemic in June 2003. However, epidemic research has indicated that SARS-CoV-2 is transmitted in humans significantly more effectively than SARS-CoV; therefore, the COVID-19 pandemic continues to expand. This indicates that the so far anti-epidemic activities to control COVID-19 are insufficient. In the current review, the possibility of using interferon α (IFN-α) as a preventive agent of COVID-19 is discussed. The current data concerning anti-COVID-19 vaccines and specific drugs against SARS-CoV-2 are also discussed. The aim of the current review is to contribute to the introduction of a more efficient strategy in the protection of the human population against COVID-19.
2019年底,中国武汉报告了一种与严重急性呼吸综合征(SARS)相似的新疾病,该疾病与SARS冠状病毒有关。很快发现,这种新疾病(COVID-19)的病因是一种此前未知的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)。COVID-19在全球的传播导致世界卫生组织宣布其在2019 - 2020年处于大流行状态,并构成国际关注的突发公共卫生事件。SARS-CoV-2具有高流行潜力,可在人与人之间有效传播。SARS-CoV和SARS-CoV-2是密切相关的病原体。它们的主要传播途径是空气飞沫传播。对抗通过吸入传播的传染病非常困难,主要依靠使用疫苗。然而,尽管缺乏有效的抗SARS-CoV疫苗和特异性抗病毒药物,但严格的卫生程序在2003年6月证明足以阻止SARS疫情。然而,流行病学研究表明,SARS-CoV-2在人与人之间的传播比SARS-CoV更有效;因此,COVID-19大流行仍在继续扩大。这表明到目前为止控制COVID-19的抗疫活动是不够的。在当前的综述中,讨论了使用干扰素α(IFN-α)作为COVID-19预防剂的可能性。还讨论了目前关于抗COVID-19疫苗和针对SARS-CoV-2的特异性药物的数据。当前综述的目的是为引入更有效的策略来保护人群免受COVID-19感染做出贡献。